Fondaparinux Sodium (Arixtra®) for the treatment of ST segment elevation myocardial infarction (STEMI)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000447
English
Authors' recommendations:
Fondaparinux (Arixtra®) should be recommended as an option for use in the treatment of ST segment elevation myocardial infarction (STEMI) in patients who are managed with thrombolytics or who are initially to receive no other form of reperfusion therapy.
Treatment with fondaparinux (Arixtra®) and its monitoring/supervision should be retained under secondary care.
AWMSG is of the opinion that fondaparinux (Arixtra®) would not be suitable for shared care within NHS Wales.
Details
Project Status:
Completed
Year Published:
2008
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=98399&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Anticoagulants
- Polysaccharides
- Myocardial Infarction
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.